Periodontal DiseasesNCT06309719
Hyaluronic Acid and Polynucleotides for Supra-bony Defects
A study testing Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA) and Periodontal Access Flap (AF) in people with Periodontal Diseases and Wound Heal, run by Queen Mary University of London at 2 sites in United Kingdom.
Trial summary
The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Periodontal Diseases, Wound Heal, Periodontal Inflammation
- What is being tested?
- Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA) and Periodontal Access Flap (AF)
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 2 sitesUnited Kingdom
- Study dates
- 21 Oct 2024to Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Systemically healthy males and females ≥18 years old
- Stage III or IV periodontitis (Papapanou, Sanz et al. 2018)
- Presence of supra-bony periodontal defects (i.e., defects where the base of the pocket is located coronal to the alveolar crest and characterized by a predominantly horizontal pattern of tissue destruction) confirmed clinically and radiographically at a minimum of two and a maximum of four adjacent teeth and with a probing pocket depth (PPD) > 5 mm, following non-surgical periodontal therapy (NSPT). If >4 adjacent teeth exhibited the above clinical and radiographic conditions, the four adjacent teeth showing the greatest overall loss of periodontal attachment were included. Wisdom teeth and second molars will not be considered for the study.
- If defect presents with an intrabony component, this should be ≤2 mm.
- Non-surgical periodontal treatment (step 1 and 2) completed within the previous 4 months
- Full-mouth bleeding score (FMBS) and full-mouth plaque score (FMPS) ≤20%
Who cannot join
- Teeth with degree III mobility
- Multi-rooted teeth with grade ≥2 furcation involvement
- Heavy smokers (≥10 cigarettes a day)
- Untreated caries or endodontic lesions or abscesses on the teeth involved in the surgery
- Previous periodontal surgery in the area selected for the study
- History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures (e.g., mitral valve prolapse, artificial heart)
Show all 11Show fewer
- Antibiotic or anticoagulant therapy during the month preceding the baseline exam.
- History of alcohol or drug abuse
- Medical history that includes uncontrolled diabetes or hepatic or renal diseases, or other serious medical conditions that can have a negative impact on the periodontal condition
- In treatment with medications that can severely affect bone metabolism and blood clot formation (e.g., anticoagulants, long-term corticosteroids, bisphosphonates, immunosuppressants)
- Self-reported pregnancy or lactation.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom2 sites, 2 recruiting
- Recruiting
Barts Health NHS Trust Dental Hospital
London, E1 1BB
Miljana Bacevic, +44(0)207 882 6348, BHNT.Clinicaloralresearchcentre@nhs.net
Elena Calciolari, DDS, MS, PhD, e.calciolari@qmul.ac.uk
- Recruiting
Centre for Oral Clinical Research (COCR)
London, E1 2AD
Miljana Bacevic, +44(0)207 882 6348, BHNT.Clinicaloralresearchcentre@nhs.net
Elena Calciolari, DDS, MS, PhD, e.calciolari@qmul.ac.uk
About this study
Official title: Characterizing the Healing of Periodontal Supra-bony Defects Treated With Hyaluronic Acid and Polynucleotides
The goal of this pilot study is to describe the early wound healing molecular events and the vascularization pattern associated with the treatment of supra-bony defects with access flap alone or in association with a combined formulation of hyaluronic acid and polydeoxyribonucleotides gel.
Read the detailed description
This is a parallel-group, pilot study aiming that consists of 7 visits over a minimum period of 4 months. Up to 24 periodontitis patients presenting with supra-bony defects will be recruited at the Centre for Oral Clinical Research (COCR) at the Institute of Dentistry, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
- Conditions
- Periodontal Diseases, Wound Heal, Periodontal Inflammation, Periodontal Pocket, Periodontal Attachment Loss
- Being tested
- Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA), Periodontal Access Flap (AF)
- Medical subject headings
- Periodontal Diseases, Periodontal Pocket, Periodontal Attachment Loss
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA)Combination product
A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). A PNHA gel will be placed on the root surfaces and supra-bony defects, followed by a tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
Periodontal Access Flap (AF)Procedure or surgery
A conservative access flap will be performed such as simplified papilla preservation flap (SPPF). No gel will be placed before suturing the flap by tension-free primary closure of the interdental papillae and of the mucoperiosteal flaps by means of 5-0 suture
| Study group | Role | What they receive |
|---|---|---|
| Test | Experimental | Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA) Receives: Combination Product: Periodontal Access Flap (AF) + Combined Formulation of Hyaluronic acid and Polydeoxyribonucleotides (PNHA) |
| Control | Active comparator | Periodontal Access Flap (AF) Receives: Procedure: Periodontal Access Flap (AF) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Early wound healing molecular events through GCF
Characterize the early wound healing molecular events through gingival crevicular fluid (GCF) biomarkers. In particular, the expression of specific biomarkers involved in the recruitment of osteoblast precursors, inflammatory-immune response, organization of extracellular matrix, cell adhesion, oxidative stress and angiogenesis. Multiplex immunoassays will be employed to simultaneously assess the expression of multiple proteins in GCF samples on the biological processes involved in early periodontal wound healing and the mechanism of action of PNHA, focusing on the expression of specific signalling pathways, including but not limited to TNF alpha, NF-kappa B, IL-17, TGF-beta, VEGF, HIF-1, Chemokine and Wnt signalling pathways.
Measured: Baseline, 1, 4, 7, 15 days and 3 months after surgery from the deepest site of one tooth involved in the surgery
Early gingival tissue vascularization pattern when supra-bony defects are treated with AF, in association or not with PNHA
Blood flow changes in the surgical area will be evaluated with Laser Speckle Contrast Imaging (LSCI)
Measured: Before and straight after completing the surgery, as well as at day 1, 4, 7, 15 and at 3 months
Secondary outcomes (16)
Periodontal parameters and periodontal inflamed surface area (PISA) on the teeth involved in the surgery
PISA reflects the surface area of bleeding pocket epithelium in square millimetres. PISA is calculated using conventional clinical attachment levels (CAL), recession (REC) and bleeding on probing (BOP) measurements. PISA quantifies the amount of inflamed periodontal tissue, thereby quantifying the inflammatory burden posed by periodontitis. The higher the number, the more inflamed periodontal tissue. The periodontal inflamed surface area (PISA) is the sum of the PPD of bleeding on probing (BOP)-positive sites for the total dentition and can be easily calculated using routine periodontal charting.
Measured: Baseline and 3 months post-surgery
Probing pocket depth (PPD)
PPD will be measured in mm using a University of North Carolina (UNC-15) periodontal probe at six sites per tooth/ implant (i.e., mesiobuccal, buccal, distobuccal, mesiolingual, lingual, and distolingual).
Measured: Baseline and 3 months post-surgery
Gingival recession (REC)
REC will be measured in mm using a University of North Carolina (UNC-15) periodontal probe at six sites per tooth/ implant (i.e., mesiobuccal, buccal, distobuccal, mesiolingual, lingual, and distolingual).
Measured: Baseline and 3 months post-surgery
Clinical attachment level (CAL)
CAL will be calculated considering the values for PPD and REC in mm
Measured: Baseline and 3 months post-surgery
Suppuration
Suppuration will be recorded as percentage of total surfaces (6 aspects per tooth/implant), which reveal the presence of suppuration following periodontal probing. A binary score will be assigned to each surface (1 for suppuration present, 0 for suppuration absent).
Measured: Baseline and 3 months post-surgery
Gingival phenotype
Gingival phenotype of the teeth involved in the surgery will be defined as thin (≤1.0 mm) or thick (>1mm) upon the observation of the periodontal probe through the gingival tissue
Measured: Baseline and 3 months post-surgery
Keratinized tissue (KT)
Keratinized tissue width will be assessed in mm with a periodontal probe measuring from the mucogingival junction to the free gingival margin.
Measured: Baseline and 3 months post-surgery
Full mouth plaque score (FMPS)
FMPS will be recorded as a percentage of total surfaces (6 sites per tooth/implant), which reveal the presence of plaque. A binary score will be assigned to each surface (1 for plaque present, 0 for absent).
Measured: Baseline and 3 months post-surgery
Full mouth bleeding score (FMBS)
FMBS will be recorded as percentage of total surfaces (6 aspects per tooth/implant), which reveal the presence of bleeding within 10 - 30 seconds following periodontal probing. A binary score will be assigned to each surface (1 for bleeding present, 0 for bleeding absent).
Measured: Baseline and 3 months post-surgery
Early Healing Index (EHI)
The surgical wound will be graded as follows:
- complete flap closure - no fibrin line in the interproximal area
- complete flap closure - fine fibrin line in the interproximal area
- complete flap closure - fibrin clot in the interproximal area
- incomplete flap closure - partial necrosis of the interproximal tissue
- incomplete flap closure - complete necrosis of the interproximal tissue.
Measured: Day 1, 4, 7 and 15 after the surgical intervention
Gingival morphometric changes
An intra-oral 3D scanner will be used to capture and monitor soft tissue contour changes during early phase of healing. A series of subtracted images from the baseline to the subsequent follow-ups will accurately identify the area and magnitude of the swelling, changes in shape and volume to monitor/quantify the healing.
Measured: Baseline visit, at 1, 4, 7, 15 days and 3 months post surgery
Oral impact on daily performance (OIDP)
OIDP focuses on the impact that the conditions of the teeth and mouth have on the physical (functional), psychological and social wellbeing of the person. For each performance, both the frequency and severity of oral impacts are assessed. The overall OIDP score ranges from 0 to 100, with higher scores indicating worse quality of life.
Measured: Baseline and at 3 months post surgery
Dentine/root sensitivity
A 100-mm horizontal visual analog scale (VAS) will be used to assess dentine/root sensitivity. The anchors for each end of the scales will be designated as none and extreme.
Measured: Baseline and at 3 months post-surgery
Food impaction
A 100-mm horizontal visual analog scale (VAS) will be used to assess food impaction. The anchors for each end of the scales will be designated as none and extreme.
Measured: Baseline and at 3 months post-surgery
Patient perception about therapy
the extent of discomfort and/or pain experienced will be evaluated using a 100-mm VAS. The anchors for each end of the scales will be designated as none and extreme.
Measured: At day 1, 4, 7 and 15 after surgical therapy
Global ratings of Periodontal Health and Quality of Life
Periodontal health and quality of life following periodontal therapy twill be investigated measured through specific questionnaries at 3 months after surgery.
Measured: 3 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2024
- Study start21 Oct 2024
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Queen Mary University of London
- Sponsor type
- University, hospital or other
- Collaborators
- Geistlich Pharma AG
- Responsible party
- Sponsor
- Investigators
- Elena Calciolari, DDS, MS, PhD, Principal investigator, QMUL
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06309719
- Sponsor's protocol ID
- 339479
- Status last verified
- Jul 2026
- First submitted
- 16 Feb 2024
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No